(Reuters) -Drug distributor McKesson raised its fiscal 2026 revenue forecast on Wednesday, betting on sturdy development in its oncology and specialty drug distribution companies.
Shares of the corporate rose about 2% in prolonged buying and selling.
Drug distributors in the US are increasing their presence available in the market for specialty medicines, which deal with complicated situations reminiscent of rheumatoid arthritis and most cancers, because of their excessive revenue margins.
McKesson now expects adjusted earnings per share within the vary of $38.35 to $38.85 for fiscal 2026, in comparison with its earlier outlook of $38.05 to $38.55 per share. Analysts, on common, anticipate a revenue of $38.33 per share, in line with information compiled by LSEG.
Earlier on Wednesday, peer Cencora additionally raised its 2026 revenue forecast and mentioned it would make investments over $1 billion by means of 2030 to broaden its U.S. community.
On an adjusted foundation, McKesson earned $9.86 per share within the quarter, beating analysts’ estimates of $9.02 per share.
The corporate reported second-quarter income of $103.15 billion, in comparison with expectations of $104.13 billion.
The drug distributor’s U.S. pharmaceutical unit — its largest section by income — recorded gross sales of $86.5 billion. That was 8% larger than final 12 months, however missed the consensus estimate of $87.40 billion.
In September, McKesson mentioned it will restructure into 4 segments to sharpen deal with high-margin companies, reminiscent of most cancers medicines, to spice up development.
(Reporting by Kamal Choudhury in Bengaluru; Enhancing by Alan Barona)